| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rare Diseases | 3 | 2020 | 360 | 0.840 |
Why?
|
| Genes, erbB-2 | 5 | 2007 | 232 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2020 | 3363 | 0.580 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1313 | 0.540 |
Why?
|
| Receptor, ErbB-2 | 6 | 2021 | 2617 | 0.450 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10627 | 0.410 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2021 | 1295 | 0.380 |
Why?
|
| Gene Amplification | 5 | 2007 | 745 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2022 | 518 | 0.310 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2019 | 1007 | 0.280 |
Why?
|
| Breast Neoplasms | 13 | 2021 | 16053 | 0.270 |
Why?
|
| Neoplasms | 4 | 2020 | 15710 | 0.210 |
Why?
|
| Cell Cycle Proteins | 3 | 2021 | 2100 | 0.210 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2021 | 523 | 0.200 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 1228 | 0.200 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2021 | 16 | 0.200 |
Why?
|
| Oxadiazoles | 1 | 2021 | 60 | 0.190 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 258 | 0.180 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2021 | 321 | 0.170 |
Why?
|
| PHD Zinc Fingers | 1 | 2019 | 4 | 0.170 |
Why?
|
| Anilides | 1 | 2021 | 288 | 0.160 |
Why?
|
| Metabolome | 1 | 2021 | 351 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2022 | 438 | 0.160 |
Why?
|
| Histone Code | 1 | 2019 | 83 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2011 | 2260 | 0.150 |
Why?
|
| Heterografts | 1 | 2020 | 750 | 0.150 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 188 | 0.140 |
Why?
|
| Prognosis | 11 | 2021 | 22249 | 0.140 |
Why?
|
| Observer Variation | 2 | 2016 | 708 | 0.140 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 240 | 0.140 |
Why?
|
| Biopsy | 2 | 2020 | 3490 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 10257 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 1149 | 0.140 |
Why?
|
| Piperidines | 1 | 2021 | 1067 | 0.130 |
Why?
|
| beta Catenin | 1 | 2019 | 697 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 261 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 375 | 0.130 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 2122 | 0.130 |
Why?
|
| Disease Progression | 4 | 2020 | 6891 | 0.120 |
Why?
|
| Mitotic Index | 1 | 2015 | 165 | 0.120 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 153 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2021 | 2560 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1059 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 518 | 0.120 |
Why?
|
| Pyridines | 1 | 2021 | 1291 | 0.120 |
Why?
|
| Female | 24 | 2022 | 147292 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2084 | 0.110 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 30813 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 867 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 1878 | 0.110 |
Why?
|
| Cell Proliferation | 4 | 2021 | 7303 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 681 | 0.110 |
Why?
|
| Tissue Array Analysis | 3 | 2015 | 764 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 1057 | 0.100 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1049 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 7429 | 0.100 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 185 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1658 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2022 | 3931 | 0.100 |
Why?
|
| Histones | 1 | 2019 | 1493 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 5531 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2095 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1899 | 0.090 |
Why?
|
| Aged | 13 | 2020 | 72902 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 3698 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1354 | 0.090 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2011 | 199 | 0.090 |
Why?
|
| Humans | 27 | 2022 | 270843 | 0.090 |
Why?
|
| Breast | 2 | 2015 | 1361 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2015 | 893 | 0.090 |
Why?
|
| Middle Aged | 13 | 2020 | 89535 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2022 | 4343 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3294 | 0.080 |
Why?
|
| Adult | 12 | 2020 | 80709 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 4895 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3623 | 0.080 |
Why?
|
| Estradiol | 1 | 2011 | 761 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 1253 | 0.080 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14855 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2012 | 620 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5295 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2014 | 1002 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 1183 | 0.070 |
Why?
|
| Apoptosis | 3 | 2021 | 7759 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2006 | 202 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2011 | 1476 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 7704 | 0.060 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 4925 | 0.060 |
Why?
|
| Mice | 6 | 2022 | 35331 | 0.060 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 13882 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2004 | 282 | 0.060 |
Why?
|
| Young Adult | 2 | 2020 | 22140 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2007 | 718 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 9067 | 0.060 |
Why?
|
| Animals | 7 | 2022 | 61014 | 0.060 |
Why?
|
| Quality Control | 1 | 2004 | 461 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2014 | 3033 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5239 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 2123 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 1904 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2004 | 304 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 4995 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 485 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2022 | 353 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 15198 | 0.050 |
Why?
|
| Male | 5 | 2020 | 127630 | 0.050 |
Why?
|
| Microarray Analysis | 2 | 2012 | 394 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 16270 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6196 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 278 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 383 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 551 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 623 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 34238 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 254 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 559 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 4452 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 4062 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2017 | 9 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 1337 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2022 | 886 | 0.040 |
Why?
|
| Mutation | 3 | 2021 | 15642 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2022 | 2403 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 1091 | 0.030 |
Why?
|
| Survival Rate | 3 | 2020 | 12451 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2019 | 579 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2019 | 1016 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 446 | 0.030 |
Why?
|
| International Agencies | 1 | 2016 | 109 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 195 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1533 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2348 | 0.030 |
Why?
|
| Cadherins | 1 | 2019 | 675 | 0.030 |
Why?
|
| Genes, erbB-1 | 2 | 2006 | 103 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 665 | 0.030 |
Why?
|
| Pathologists | 1 | 2016 | 99 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1808 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 5511 | 0.030 |
Why?
|
| Genes, myc | 2 | 2006 | 360 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 360 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3518 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 991 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 505 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 2520 | 0.030 |
Why?
|
| Cyclin D1 | 2 | 2005 | 582 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 5030 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2012 | 227 | 0.030 |
Why?
|
| Androgens | 1 | 2015 | 519 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1084 | 0.030 |
Why?
|
| Caspases, Initiator | 1 | 2011 | 17 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2011 | 69 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 296 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 120 | 0.020 |
Why?
|
| Genotype | 1 | 2019 | 4168 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14506 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 1560 | 0.020 |
Why?
|
| Protein Folding | 1 | 2011 | 292 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 2819 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2012 | 264 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 722 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5242 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 627 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2011 | 460 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1335 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 770 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2019 | 39512 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9487 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 2114 | 0.020 |
Why?
|
| Cyclin D | 1 | 2006 | 37 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2006 | 110 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2006 | 117 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 3974 | 0.020 |
Why?
|
| Switzerland | 1 | 2005 | 30 | 0.020 |
Why?
|
| Saudi Arabia | 1 | 2005 | 39 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 1415 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 2210 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 1997 | 0.020 |
Why?
|
| Cyclins | 1 | 2006 | 466 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3148 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2012 | 4887 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 504 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 2428 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 12151 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 18267 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2004 | 840 | 0.010 |
Why?
|
| Epithelium | 1 | 2004 | 729 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6269 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2011 | 2917 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10093 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 835 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 1559 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 1929 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 7738 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 2317 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 4386 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2005 | 2329 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7908 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 9324 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 3385 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 4911 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 5716 | 0.010 |
Why?
|